| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3)：209-249.
|
| [2] |
de Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer[J]. N Engl J Med, 2009, 361(7)：653-663.
|
| [3] |
Hansen NM, Ye X, Grube BJ, et al. Manipulation of the primary breast tumor and the incidence of sentinel node metastases from invasive breast cancer[J]. Arch Surg, 2004, 139(6)：634-639.
|
| [4] |
Liikanen J, Leidenius M, Joensuu H, et al. Breast cancer prognosis and isolated tumor cell findings in axillary lymph nodes after core needle biopsy and fine needle aspiration cytology: biopsy method and breast cancer outcome[J]. Eur J Surg Oncol, 2016, 42(1)：64-70.
|
| [5] |
Diaz NM, Cox CE, Ebert M, et al. Benign mechanical transport of breast epithelial cells to sentinel lymph nodes[J]. Am J Surg Pathol, 2004, 28(12)：1641-1645.
|
| [6] |
马清梅，罗佳，李家平等．超声造影在乳腺癌原发灶切除后前哨淋巴结的价值[J].中山大学学报(医学科学版)，2023，44(4)：663-667.
|
| [7] |
Saphir O, Amromin GD. Obscure axillary lymph node metastasis in carcinoma of the breast[J]. Am J Pathol, 1948, 24(3)：726.
|
| [8] |
Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual[J]. Surg Clin North Am, 2003, 83(4)：803-819.
|
| [9] |
Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18[J]. Cancer, 2002, 95(4)：681-695.
|
| [10] |
Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Clin Oncol, 1997, 15(7)：2483-2493.
|
| [11] |
van Nijnatten TJ, Simons JM, Moossdorff M, et al. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases[J]. Breast Cancer Res Treat, 2017, 163(1)：159-166.
|
| [12] |
Kantor O, Wong S, Weiss A, et al. Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer[J]. NPJ Breast Cancer, 2020, 6：35.
|
| [13] |
Lai BS, Tsang JY, Li JJ, et al. Anatomical site and size of sentinel lymph node metastasis predicted additional axillary tumour burden and breast cancer survival[J]. Histopathology, 2023, 82(6)：899-911.
|
| [14] |
Liikanen JS, Leidenius MH, Joensuu H, et al. Prognostic value of isolated tumour cells in sentinel lymph nodes in early-stage breast cancer: a prospective study[J]. Br J Cancer, 2018, 118(11)：1529-1535.
|
| [15] |
Andersson Y, Bergkvist L, Frisell J, et al. Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes[J]. Breast Cancer Res Treat, 2018, 171(2)：359-369.
|
| [16] |
Li Y, Zhang H, Zhang W, et al. A competing risk analysis model to determine the prognostic value of isolated tumor cells in axillary lymph nodes for T1N0M0 breast cancer patients based on the Surveillance, Epidemiology, and End Results Database[J]. Front Oncol, 2020, 10：572 316.
|
| [17] |
Houvenaeghel G, de Nonneville A, Cohen M, et al. Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort[J]. ESMO Open, 2021, 6(3)：100 151.
|
| [18] |
Gobardhan PD, Elias SG, Madsen EV, et al. Prognostic value of lymph node micrometastases in breast cancer: a multicenter cohort study[J]. Ann Surg Oncol, 2011, 18(6)：1657-1664.
|
| [19] |
Maaskant-Braat AJ, van de Poll-Franse LV, Voogd AC, et al. Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study[J]. Breast Cancer Res Treat, 2011, 127(1)：195-203.
|
| [20] |
Copur MS. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer[J]. N Engl J Med, 2021, 384(12)：1176.
|
| [21] |
Herbert GS, Sohn VY, Brown TA. The impact of nodal isolated tumor cells on survival of breast cancer patients[J]. Am J Surg, 2007, 193(5)：571-573.
|
| [22] |
van der Heiden－van der Loo M, Schaapveld M, Ho VK, et al. Outcomes of a population-based series of early breast cancer patients with micrometastases and isolated tumour cells in axillary lymph nodes[J]. Ann Oncol, 2013, 24(11)：2794-2801.
|
| [23] |
Wong SM, Almana N, Choi J, et al. Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer[J]. Ann Surg Oncol, 2019, 26(11)：3502-3509.
|
| [24] |
Tsuda H. Histological examination of sentinel lymph nodes: significance of macrometastasis, micrometastasis, and isolated tumor cells[J]. Breast Cancer, 2015, 22(3)：221-229.
|
| [25] |
de Boer M, van Dijck JA, Bult P, et al. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases[J]. J Natl Cancer Inst, 2010, 102(6)：410-425.
|
| [26] |
Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial[J]. Lancet Oncol, 2013, 14(4)：297-305.
|
| [27] |
Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial[J]. JAMA, 2011, 305(6): 569-575.
|
| [28] |
Sasada S, Masumoto N, Emi A, et al. Clinical effect of the pathological axillary assessment method in breast cancer without clinical nodal metastasis[J]. Breast Cancer, 2021, 28(5)：1016-1022.
|
| [29] |
Cabıoǧlu N, Karanlık H, Yıldırım N, et al. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study[J]. Eur J Surg Oncol, 2021, 47(10)：2506-2514.
|
| [30] |
Cavalcante FP, Zerwes F, Millen EC, et al. Management of the positive sentinel lymph node following neoadjuvant chemotherapy: results of a survey conducted with breast surgeons[J]. Ecancermedicalscience, 2022, 16：1357.
|
| [31] |
Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021[J]. Ann Oncol, 2021, 32(10)：1216-1235.
|
| [32] |
Kantor O, Wakeman M, Weiss A, et al. Axillary management after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer[J]. Ann Surg Oncol, 2021, 28(3)：1358-1367.
|
| [33] |
Cox CE, Kiluk JV, Riker AI, et al. Significance of sentinel lymph node micrometastases in human breast cancer[J]. J Am Coll Surg, 2008, 206(2)：261-268.
|
| [34] |
Pepels MJ, de Boer M, Bult P, et al. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells[J]. Ann Surg, 2012, 255(1)：116-121.
|
| [35] |
Moo TA, Edelweiss M, Hajiyeva S, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection？[J]. Ann Surg Oncol, 2018, 25(6)：1488-1494.
|
| [36] |
Franceschini G, Di Leone A, Sanchez AM, et al. Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient[J]. Ann Ital Chir, 2020, 91：465-468.
|
| [37] |
Rubio IT, Aznar F, Lirola J, et al. Intraoperative assessment of sentinel lymph nodes after neoadjuvant chemotherapy in patients with breast cancer[J]. Ann Surg Oncol, 2010, 17(1)：235-239.
|
| [38] |
Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial[J]. Lancet Oncol, 2018, 19(10)：1385-1393.
|
| [39] |
Dutta SW, Volaric A, Morgan JT, et al. Pathologic evaluation and prognostic implications of nodal micrometastases in breast cancer[J]. Semin Radiat Oncol, 2019, 29(2)：102-110.
|
| [40] |
Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2022, NCCNClinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2022, 20(6): 691-722.
|
| [41] |
Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline updater[J]. J Clin Oncol, 2022, 40(16): 1816-1837.
|
| [42] |
中国临床肿瘤学会指南工作委员会．中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2023[M].北京：人民卫生出版社，2023：74.
|
| [43] |
程红莲，王梦，余岳，等．早期乳腺癌新辅助化疗淋巴结转阴患者术后放疗的价值[J].天津医药，2020，48(1)：45-50.
|
| [44] |
Wang Q, Zhao J, Han X, et al. Is there a role for post-mastectomy radiotherapy for T1-2N1 breast cancers with node-positive pathology after patients become node-negative pathology following neoadjuvant chemotherapy？[J]. Front Oncol，2020，10：892.
|
| [45] |
Wang Q, Zheng K, Zhang L, et al. The treatment process of an extremely rare giant borderline phyllodes tumor of breast: case report and literature review[J]. Transl Cancer Res, 2021, 10(4)：1921-1929.
|
| [46] |
Mamtani A, Patil S, Stempel M, et al. Axillary micrometastases and isolated tumor cells are not an indication for post-mastectomy radiotherapy in stage 1 and 2 breast cancer[J]. Ann Surg Oncol, 2017, 24(8)：2182-2188.
|
| [47] |
Kim JK, Karp JM, Gerber NK. Regional nodal irradiation (RNI) in breast cancer patients with residual isolated tumor cells or micrometastatic nodal disease after neoadjuvant chemotherapy[J]. Clin Transl Radiat Oncol, 2023, 38：195-201.
|